User profiles for Markus Riester

Markus Riester

Novartis Institutes for Biomedical Research
Verified email at novartis.com
Cited by 7767

[PDF][PDF] Specific effects of microRNAs on the plant transcriptome

R Schwab, JF Palatnik, M Riester, C Schommer… - Developmental cell, 2005 - cell.com
Most plant microRNAs (miRNAs) have perfect or near-perfect complementarity with their
targets. This is consistent with their primary mode of action being cleavage of target mRNAs, …

Highly Specific Gene Silencing by Artificial MicroRNAs in Arabidopsis

R Schwab, S Ossowski, M Riester, N Warthmann… - The Plant …, 2006 - academic.oup.com
Plant microRNAs (miRNAs) affect only a small number of targets with high sequence
complementarity, while animal miRNAs usually have hundreds of targets with limited …

Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia

…, X Han, C Tribouley, PA Wood, RJ Leary, M Riester… - Nature medicine, 2018 - nature.com
We identified genetic mutations in CD19 and loss of heterozygosity at the time of CD19 –
relapse to chimeric antigen receptor (CAR) therapy. The mutations are present in the vast …

[HTML][HTML] Most human non-GCIMP glioblastoma subtypes evolve from a common proneural-like precursor glioma

T Ozawa, M Riester, YK Cheng, JT Huse, M Squatrito… - Cancer cell, 2014 - cell.com
To understand the relationships between the non-GCIMP glioblastoma (GBM) subgroups, we
performed mathematical modeling to predict the temporal sequence of driver events during …

JAK–STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response

M Kleppe, M Kwak, P Koppikar, M Riester, M Keller… - Cancer discovery, 2015 - AACR
The identification of JAK2/MPL mutations in patients with myeloproliferative neoplasms (MPN)
has led to the clinical development of JAK kinase inhibitors, including ruxolitinib. …

Combination of a novel gene expression signature with a clinical nomogram improves the prediction of survival in high-risk bladder cancer

M Riester, JM Taylor, A Feifer, T Koppie… - Clinical cancer …, 2012 - AACR
Purpose: We aimed to validate and improve prognostic signatures for high-risk urothelial
carcinoma of the bladder. Experimental Design: We evaluated microarray data from 93 patients …

Risk prediction for late-stage ovarian cancer by meta-analysis of 1525 patient samples

M Riester, W Wei, L Waldron… - Journal of the …, 2014 - academic.oup.com
Background Ovarian cancer causes more than 15000 deaths per year in the United States.
The survival of patients is quite heterogeneous, and accurate prognostic tools would help …

[HTML][HTML] TGFβ-blockade uncovers stromal plasticity in tumors by revealing the existence of a subset of interferon-licensed fibroblasts

…, ND Kirkpatrick, J Wu, A DeWeck, M Riester… - Nature …, 2020 - nature.com
Despite the increasing interest in targeting stromal elements of the tumor microenvironment,
we still face tremendous challenges in developing adequate therapeutics to modify the …

[HTML][HTML] curatedOvarianData: clinically annotated data for the ovarian cancer transcriptome

BF Ganzfried, M Riester, B Haibe-Kains, T Risch… - Database, 2013 - academic.oup.com
This article introduces a manually curated data collection for gene expression meta-analysis
of patients with ovarian cancer and software for reproducible preparation of similar …

Evolution of the cancer genome

O Podlaha, M Riester, S De, F Michor - Trends in Genetics, 2012 - cell.com
Human tumors result from an evolutionary process operating on somatic cells within tissues,
whereby natural selection operates on the phenotypic variability generated by the …